Test performance (sensitivity and specificity) · Apparently healthy adults aged 35 years or older (general population), living in 13 clusters in rural areas of Trivandrum city, Kerala,…
1 finding from 1 review
Survival (proportion alive after diagnosis) · Apparently healthy adults aged 35 years or older (general population), living in 13 clusters in rural areas of Trivandrum city, Kerala,…
1 finding from 1 review
Inter-examiner reliability · Children and adults with primary or permanent dentition
Inter-examiner kappa statistics ranged from 0.44 to 0.91 across 13 studies; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
no estimate extracted
13 studies
GRADE not reported
Positive predictive value for dental caries diagnosis · Children and adults with primary or permanent dentition
Positive predictive values were reported in 10 of the 13 studies that reported sensitivity and specificity; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
no estimate extracted
10 studies
GRADE not reported
Negative predictive value for dental caries diagnosis · Children and adults with primary or permanent dentition
Negative predictive values were reported in 10 of the 13 studies that reported sensitivity and specificity; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
no estimate extracted
10 studies
GRADE not reported
Intra-examiner reliability · Children and adults with primary or permanent dentition
Intra-examiner kappa statistics ranged from 0.52 to 1.00 across 6 studies; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
no estimate extracted
6 studies
GRADE not reported
Sensitivity for dental caries diagnosis · Children and adults with primary or permanent dentition
Sensitivity ranged from 48% to 98.3% across 13 studies; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
d/D dft/DFT or dmft/DMFT score differences · Children and adults with primary or permanent dentition
Eight studies calculated caries-score differences; six reported no significant difference, one underestimation, and one overestimation with teledentistry.
1 finding from 1 review
no estimate extracted
8 studies
GRADE not reported
Specificity for dental caries diagnosis · Children and adults with primary or permanent dentition
Specificity ranged from 83% to 100% across 13 studies; no meta-analysis or GRADE rating was reported.
1 finding from 1 review
no estimate extracted
13 studies
GRADE not reported
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).
1 finding from 1 review
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Change in disability score · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
31 participants
Low
Muscle strength · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
30 participants
Low
Acquiring the ability to stand or walk · ambulatory adults with SMA type III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
28 participants
Moderate
Change in pulmonary function · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
24 participants
Low
Time from beginning of treatment until death or full‐time ventilation · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
33 participants
Low
Adverse events related to treatment · ambulatory adults with SMA type III
Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
RR 0.8 [0.44, 1.44]
33 participants
Low
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found